natgillin/translations-raw huggingface dataset:
Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4). 
Terapevtskih izkušnj pri bolnikih z zmerno boleznijo jeter, ki imajo lahko hemoragično diatezo, je malo (glejte poglavje 4.4).
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Če bolnik izpusti odmerek: - če je zamuda manj kot 12 ur po pravem času za odmerek: bolnik naj odmerek vzame takoj,
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies. 
Bolniki so bili naključno razporejeni v skupino, ki je prejemala klopidogrel (začetni odmerek 300 mg, nato 75 mg/dan, N=6.259) in ASA (75-325 mg enkrat dnevno) ali samo ASA (N=6.303), (75-325 mg enkrat dnevno) in drugimi standardnimi terapijami.
Patients should be counseled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy. 
Bolnike je treba opozoriti o povečani nevarnosti gastrointestinalnih poškodb in krvavitev pri sočasnem zaužitju klopidogrela in ASA z alkoholom, še posebej, če gre za veliko ali kronično rabo alkohola (glejte poglavje 4.5).
Each film-coated tablet contains 7 mg of lactose and 3.3 mg of hydrogenated castor oil. 
Ena filmsko obložena tableta vsebuje 7 mg laktoze in 3,3 mg hidrogeniranega ricinusovega olja.
Interactions with the following medicinal products with higher (anti-inflammatory) doses of ASA have also been reported: angiotensin converting enzyme (ACE) inhibitors, phenytoin, beta blockers, diuretics, and oral hypoglycemic agents. 
Med uporabo večjih (protivnetnih) odmerkov ASA so opisane interakcije z naslednjimi zdravili: zaviralci angiotenzin konvertaze (ACE), fenitoin, zaviralci adrenergičnih receptorjev beta, diuretiki in peroralnimi antidiabetiki.
Jaundice (yellowing of skin and/or eyes); burning in stomach and/or esophagus (gullet); severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of foods, inflammation of small vessels. 
Zelo redki neželeni učinki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): Zlatenica (porumenelost kože in/ali oči), pekoč občutek v želodcu in/ali požiralniku (grlu), huda bolečina v trebuhu z ali brez bolečine v hrbtu, zvišana telesna temperatura, težave pri dihanju, ki so včasih povezane s kašljem, splošne alergijske reakcije (na primer, splošni občutek toplote z nenadnim nelagodjem do nezavesti), oteklina v ustih, mehurji na koži, kožna alergija, vnetje v ustih (stomatitis), znižanje krvnega tlaka, zmedenost, halucinacije, bolečine v sklepih, bolečine v mišicah, motnje okusa ali izguba okusa, vnetje malih žil.
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) plus ASA or ASA alone (n=1,739), (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg dnevno, n=1.752) in ASA ali samo ASA (n=1.739), (150 mg do 325 mg kot udarni odmerek, nato 75 mg do 162 mg dnevno), fibrinolitičnim sredstvom in po potrebi heparinom.
DuoPlavin is supplied in cardboard cartons containing: - 14, 28 and 84 tablets in all-aluminium blisters - 30x1, 50x1, 90x1 and 100x1 tablet in all-aluminium perforated unit-dose blisters. 
Zdravilo DuoPlavin je na voljo v kartonskih škatlah, ki vsebujejo: - 14, 28, 84 tablet v pretisnih omotih iz aluminija - 30 x 1, 50 x 1, 90 x 1 in 100 x 1 tableto v aluminijastih perforiranih pretisnih omotih za enkratni odmerek.
Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn. 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1od 10 bolnikov): Driska, bolečine v trebuhu, težave z želodcem ali zgaga.
Patients received clopidogrel (75 mg/day, n=22,961) plus ASA (162 mg/day), or ASA alone (162 mg/day) (n=22,891), for 28 days or until hospital discharge. 
Bolniki so 28 dni oziroma do odpusta dobivali klopidogrel (75 mg dnevno, n=22.961) in ASA (162 mg dnevno), ali samo ASA (162 mg dnevno, n=22.891).
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Triacetin (E1518) Red iron oxide (E172) 
Obloga laktoza monohidrat hipromeloza (E464) titanov dioksid (E171) triacetin (E1518) rdeči železov oksid (E172)
Do not take DuoPlavin 
Ne jemljite zdravila DuoPlavin:
If you forget to take DuoPlavin 
Če ste pozabili vzeti zdravilo DuoPlavin:
Following absorption, the ASA in DuoPlavin is hydrolyzed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing. 
Salicilna kislina doseže največjo koncentracijo v plazmi v 1 uri po uporabi zdravila, tako da je koncentracija ASA v plazmi po 1,5 do 3 urah po uporabi praktično nezaznavna.
Hypoglycaemia*, gout* (see section 4.4) 
Presnovne in prehranske motnje hipoglikemija*, protin* (glejte poglavje 4.4)
While you are taking DuoPlavin: 
Ko jemljete zdravilo DuoPlavin:
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Triacetin (E1518) Yellow iron oxide (E172) 
Obloga laktoza monohidrat hipromeloza (E464) titanov dioksid (E171) triacetin (E1518) rumeni železov oksid (E172)
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus, fixed eruption* 
Hypersensitivity Syndrome), kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS, Drug Rash with Eosinophilia and Systemic Symptoms), eritematozen ali eksfoliativen izpuščaj, urtikarija, ekcem, lihen planus, fiksen izpuščaj*
If you stop taking DuoPlavin 
Če ste prenehali jemati zdravilo DuoPlavin:
The concomitant administration of DuoPlavin with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.5). 
Sočasna uporaba zdravila DuoPlavin in varfarina ni priporočljiva, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
Aluminium perforated unit-dose blisters in cardboard cartons containing 30x1, 50x1, 90x1 and 100x1 film-coated tablet. 
Aluminijasti perforirani pretisni omoti za enkratni odmerek v kartonskih škatlah, ki vsebujejo 30 x 1, 50 x 1, 90 x 1 in 100 x 1 filmsko obloženo tableto.
Renal failure*, acute renal impairment (especially in patients with existing renal impairment, heart decompensation, nephritic syndrome, or concomitant treatment with diuretics)*, glomerulonephritis, blood creatinine increased 
Zelo redki ali ni znano nefritičnim sindromom ali sočasnim zdravljenjem z diuretiki)*, glomerulonefritis, zvišanje kreatinina v krvi
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4) 
Trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), odpoved kostnega mozga*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija, hemolitična anemija pri bolnikih s
• This medicinal product must be administered under close medical supervision in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of haemolysis (see section 
• Pri bolnikih s pomanjkanjem glukoza-6-fosfat-dehidrogenaze (G6PD) je treba to zdravilo uporabljati pod natančnim zdravniškim nadzorom, ker pri njih obstaja tveganje za hemolizo (glejte poglavje 4.8).
DuoPlavin 75 mg/75 mg film-coated tablets (tablets) are oval, slightly biconvex, yellow, engraved on one side with ‘C75' and ‘A75'on the other side. 
Zdravilo DuoPlavin 75 mg/75 mg filmsko obložene tablete (tablete) so ovalne, rahlo bikonveksne, rumene, z vtisnjeno oznako «C75» na eni strani in «A75» na drugi strani.
DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin should be given as a single daily 75 mg/75 mg dose. 
DuoPlavin 75 mg/75 mg filmsko obložene tablete Zdravilo DuoPlavin se mora dajati kot enkratni dnevni odmerek 75 mg/75 mg.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Warnings and precautions'). 
Vendar pa se morate takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila DuoPlavin«).
This leaflet was last revised in <Month YYYY>. 
Navodilo je bilo nazadnje revidirano
DuoPlavin 75 mg/100 mg film-coated tablets DuoPlavin should be given as a single daily 75 mg/100 mg dose. 
DuoPlavin 75 mg/100 mg filmsko obložene tablete Zdravilo DuoPlavin se mora dajati kot enkratni dnevni odmerek 75 mg/100 mg.
The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4. 
Aktivni presnovek nastane predvsem z delovanjem CYP2C19, k nastanku pa pripomorejo tudi drugi encimi CYP, vključno s CYP1A2, CYP2B6 in CYP3A4.In vitro izolirani aktivni tiolski presnovek se hitro in ireverzibilno veže na trombocitne receptorje in tako zavre agregacijo trombocitov.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER / 30, 30x1, 50x1, 90x1 and 100x1 tablets 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU Pretisni omot / 30, 30x1, 50x1, 90x1 in 100x1 tablet
Patients should also be told that it might take longer than usual to stop bleeding when they take DuoPlavin, and that they should report any unusual bleeding (site or duration) to their physician. 
Naročiti jim morate, naj o vsaki krvavitvi, ki je neobičajna (glede na mesto ali trajanje), obvestijo svojega zdravnika.
DuoPlavin 75 mg/100 mg film-coated tablets (tablets) are oval, slightly biconvex, light pink, engraved on one side with ‘C75' and ‘A100'on the other side. 
DuoPlavin 75 mg/100 mg filmsko obložene tablete Svetlo rožnata, ovalna, rahlo bikonveksna, z vtisnjeno oznako "C75" na eni strani in "A100" na drugi strani.
Upper gastrointestinal disorders (oesophagitis, oesophageal ulceration, perforation, erosive gastritis, erosive duodenitis; gastro-duodenal ulcer/perforations)*; lower gastrointestinal disorders (small [jejunum and ileum] and large [colon and rectum] intestinal ulcers, colitis and intestinal perforation)*; upper gastro-intestinal symptoms* such as gastralgia (see section 4.4); these ASArelated GI reactions may or may not be associated with haemorrhage, and may occur at any dose of acetylsalicylic acid and in patients with or without warning symptoms or a previous history of serious GI events*. 
Krvavitev v prebavila in retroperitonealna krvavitev (opisani so primeri s smrtnim izidom), pankreatitis, bolezni zgornjih prebavil (ezophagitis (vnetje sluznice požiralnika), ulkus požiralnika (razjede v požiralniku), perforacija (predrtje), erozivni gastritis, erozivni duodenitis; razjede/perforacije na želodcu/dvanajstniku)*, bolezni spodnjih prebavil (ulkusi (peptične razjede) tankega [jejunum in ileum] in debelega črevesa [kolon in rektum (danka)], kolitis in perforacije prebavil) *, simptomi zgornjih prebavil*, npr. gastralgija (glejte poglavje 4.4), te, z acetilsalicilno kislino (ASA) povezane gastrointestinalne (GI) reakcije, so lahko ali pa tudi ne povezane s krvavitvijo.
Microcrystalline cellulose Low substituted hydroxypropylcellulose Maize starch 
Jedro manitol (E421) makrogol 6000 mikrokristalna celuloza nizko substituirana hidroksipropilceluloza koruzni škrob hidrogenirano ricinusovo olje stearinska kislina brezvodni koloidni silicijev dioksid
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction. 
Acetilsalicilna kislina zavira agregacijo trombocitov z ireverzibilnim zavrtjem prostaglandinske ciklooksigenaze.
Varicella vaccine 
Žilne bolezni
• medicines that may increase your risk of bleeding such as: - oral anticoagulants, medicines used to reduce blood clotting, - ASA or another non-steroidal anti-inflammatory medicine usually used to treat painful and/or inflammatory conditions of muscle or joints, - heparin or any other injectable medicine used to reduce blood clotting, - ticlopidine, other antiplatelet agent, 
Zdravniku morate posebej povedati, če jemljete - zdravila, ki lahko povečajo tveganje za krvavitve, kot so: o peroralne antikoagulanse, zdravila proti strjevanju krvi, o ASA ali kakšno drugo nesteroidno protivnetno zdravilo, ki jih ponavadi uporabljamo za zdravljenje bolečin in/ali vnetja mišic ali sklepov, o heparin ali drugo zdravilo v obliki injekcij proti strjevanju krvi, o tiklopidin, drugo antiagregacijsko zdravilo, o selektivni zaviralci privzema serotonina (vključno a ne omejeno na fluoksetin ali fluvoksamin), zdravila, ki se običajno uporabljajo za zdravljenje depresije, - omeprazol ali esomeprazol, zdravila za zdravljenje težav z želodcem, - metotreksat, zdravilo za zdravljenje hude bolezni sklepov (revmatoidnega artritisa) ali bolezni kože (luskavice),
The other ingredients are: - Tablet core: mannitol (E421), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil (see section 2 ‘DuoPlavin contains hydrogenated castor oil'), stearic acid and colloidal anhydrous silica - Tablet coating: lactose monohydrate (see section 2 ‘DuoPlavin contains lactose'), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), red iron oxide (E172) - Polishing agent: carnauba wax 
Pomožne snovi so: - Jedro tablete: manitol (E421), makrogol 6000, mikrokristalna celuloza, nizko substituirana hidroksipropilceluloza, koruzni škrob, hidrogenirano ricinusovo olje (glejte poglavje 2 ‘Zdravilo DuoPlavin vsebuje hidrogenirano ricinusovo olje'), stearinska kislina in brezvodni koloidni silicijev dioksid.
Bleeding at the puncture site 
Krvavitve na mestu vboda
How to store DuoPlavin 
Shranjevanje zdravila DuoPlavin
DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin 75 mg/100 mg film-coated tablets 
DuoPlavin 75 mg/75 mg filmsko obložene tablete DuoPlavin 75 mg/100 mg filmsko obložene tablete
EU/1/10/619/008 14 film-coated tablets EU/1/10/619/009 28 film-coated tablets EU/1/10/619/010 30x1 film-coated tablet EU/1/10/619/011 50x1 film-coated tablet EU/1/10/619/012 84 film-coated tablets EU/1/10/619/013 90x1 film-coated tablet EU/1/10/619/014 100x1 film-coated tablet 
EU/1/10/619/008 14 filmsko obloženih tablet EU/1/10/619/009 28 filmsko obloženih tablet EU/1/10/619/010 30 x 1 filmsko obloženih tablet EU/1/10/619/011 50 x 1 filmsko obloženih tablet EU/1/10/619/012 84 filmsko obloženih tablet EU/1/10/619/013 90 x 1 filmsko obloženih tablet EU/1/10/619/014 100 x 1 filmsko obloženih tablet
EU/1/10/619/001 14 film-coated tablets EU/1/10/619/002 28 film-coated tablets EU/1/10/619/003 30x1 film-coated tablet EU/1/10/619/004 50x1 film-coated tablet EU/1/10/619/005 84 film-coated tablets EU/1/10/619/006 90x1 film-coated tablet EU/1/10/619/007 100x1 film-coated tablet EU/1/10/619/015 30 film-coated tablets 
EU/1/10/619/001 14 filmsko obloženih tablet EU/1/10/619/002 28 filmsko obloženih tablet EU/1/10/619/003 30 x 1 filmsko obloženih tablet EU/1/10/619/004 50 x 1 filmsko obloženih tablet EU/1/10/619/005 84 filmsko obloženih tablet EU/1/10/619/006 90 x 1 filmsko obloženih tablet EU/1/10/619/007 100 x 1 filmsko obloženih tablet EU/1/10/619/015 30 filmsko obloženih tablet
DuoPlavin 75 mg/75 mg film-coated tablets 
DuoPlavin 75 mg/75 mg filmsko obložene tablete
You should stop other clopidogrel treatment while you are taking DuoPlavin. 
Če jemljete zdravilo DuoPlavin prenehajte jemati klopidogrel.
DuoPlavin 75 mg/75 mg film-coated tablets EU/1/10/619/001 - Cartons of 14 film-coated tablets in aluminium blister packs EU/1/10/619/002 - Cartons of 28 film-coated tablets in aluminium blister packs EU/1/10/619/003 - Cartons of 30x1 film-coated tablet in aluminium blister packs EU/1/10/619/004 - Cartons of 50x1 film-coated tablet in aluminium blister packs EU/1/10/619/005 - Cartons of 84 film-coated tablets in aluminium blister packs EU/1/10/619/006 - Cartons of 90x1film-coated tablet in aluminium blister packs EU/1/10/619/007 - Cartons of 100x1film-coated tablet in aluminium blister packs EU/1/10/619/015 - Cartons of 30 film-coated tablet in aluminium blister packs 
DuoPlavin 75 mg/75 mg filmsko obložene tablete EU/1/10/619/001 - Škatle s 14 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/10/619/002 - Škatle z 28 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/10/619/003 - Škatle s 30 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih EU/1/10/619/004 - Škatle s 50 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih EU/1/10/619/005 - Škatle s 84 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/10/619/006 - Škatle z 90 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih EU/1/10/619/007 - Škatle s 100 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih EU/1/10/619/015 - Škatle s 30 filmsko obloženimi tabletami v aluminijastih pretisnih omotih
Hearing loss* or tinnitus* 
Tinitus* ali poslabšanje sluha*
DuoPlavin 75 mg/100 mg film-coated tablets 
DuoPlavin 75 mg/100 mg filmsko obložene tablete
DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in: 
Zdravilo DuoPlavin je na voljo v kartonskih škatlah, ki vsebujejo:
DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid 
DuoPlavin 75 mg/75 mg filmsko obložene tablete DuoPlavin 75 mg/100 mg filmsko obložene tablete klopidogrel in acetilsalicilna kislina
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. Heparin, ATC Code: B01AC30. 
Oznaka ATC: B01AC30.
• Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention 
DuoPlavin je kombinirano zdravilo s stalnim odmerkom za nadaljevalno zdravljenje pri: - akutnem koronarnem sindromu brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bila vstavljena opornica po perkutani koronarni intervenciji, - akutnem miokardnem infarktu z elevacijo ST spojnice pri bolnikih, ki se zdravijo z zdravili in so primerni za trombolitično zdravljenje.
DuoPlavin 75 mg/100 mg film-coated tablets EU/1/10/619/008 - Cartons of 14 film-coated tablets in aluminium blister packs EU/1/10/619/009 - Cartons of 28 film-coated tablets in aluminium blister packs EU/1/10/619/010 - Cartons of 30x1 film-coated tablet in aluminium blister packs EU/1/10/619/011 - Cartons of 50x1 film-coated tablet in aluminium blister packs EU/1/10/619/012 - Cartons of 84 film-coated tablets in aluminium blister packs EU/1/10/619/013 - Cartons of 90x1 film-coated tablet in aluminium blister packs EU/1/10/619/014 - Cartons of 100x1 film-coated tablet in aluminium blister packs 
DuoPlavin 75 mg/100 mg filmsko obložene tablete EU/1/10/619/008 - Škatle s 14 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/10/619/009 - Škatle z 28 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/10/619/010 - Škatle s 30 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih EU/1/10/619/011 - Škatle s 50 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih EU/1/10/619/012 - Škatle s 84 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/10/619/013 - Škatle z 90 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih EU/1/10/619/014 - Škatle s 100 x 1 filmsko obloženo tableto v aluminijastih pretisnih omotih
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid (ASA). 
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (kot hidrogensulfata) in 75 mg acetilsalicilne kisline (ASA).
Colitis (including ulcerative or lymphocytic colitis), stomatitis, acute pancreatitis in the context of a hypersensitivity reaction due to acetylsalicylic acid* 
Zelo redki ali ni znano stomatitis, akutni pankreatitis v okviru preobčutljivostne reakcije zaradi acetilsalicilne kisline *
DuoPlavin 75 mg/100 mg film-coated tablets Aluminium blisters in cardboard cartons containing 14, 28 and 84 film-coated tablets. 
Aluminijasti pretisni omoti v kartonskih škatlah, ki vsebujejo 14, 28 in 84 filmsko obloženih tablet.
- Tablet core: mannitol (E421), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil (see section 2 ‘DuoPlavin contains hydrogenated castor oil'), stearic acid and colloidal anhydrous silica - Tablet coating: lactose monohydrate (see section 2 ‘DuoPlavin contains lactose'), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), yellow iron oxide (E172) - Polishing agent: carnauba wax 
- Obloga tablete: laktoza monohidrat (glejte poglavje 2 ‘Zdravilo DuoPlavin vsebuje laktozo') , hipromeloza (E464), titanov dioksid (E171), triacetin (E1518) in rumeni železov oksid (E172) - Polirno sredstvo: karnauba vosek.
The safety of the concomitant administration of DuoPlavin with other thrombolytic agents has not been formally established and should be undertaken with caution (see section 4.4). 
Varnost sočasne uporabe zdravila DuoPlavin z drugimi trombolitiki ni formalno ugotovljena.
Therapeutic experience is limited in patients with mild to moderate renal impairment (see section 4.4). 
Zdravilo DuoPlavin se ne sme uporabljati pri bolnikih s hudo okvaro ledvic (glejte poglavje 4.3).Terapevtskih izkušenj pri bolnikih z blago do zmerno okvaro ledvic je malo (glejte poglavje 4.4).
Sanofi S.p.A. Tel: 800.536 389 
Tel: 800. 536 389
DuoPlavin 75 mg/75 mg film-coated tablets Aluminium blisters in cardboard cartons containing 14, 28, 30 and 84 film-coated tablets. 
Aluminijasti pretisni omoti v kartonskih škatlah, ki vsebujejo 14, 28,30 in 84 filmsko obloženih tablet.
Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid. 
Ena tableta vsebuje 75 mg klopidogrela (kot hidrogensulfata) in 75 mg acetilsalicilne kisline.
Each tablet contains: 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid. 
Ena tableta vsebuje: 75 mg klopidogrela (kot hidrogensulfata) in 100 mg acetilsalicilne kisline.
Each tablet contains: 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid. 
Ena tableta vsebuje: 75 mg klopidogrela (kot hidrogensulfata) in 75 mg acetilsalicilne kisline.
What DuoPlavin contains 
Kaj vsebuje zdravilo DuoPlavin
Bleeding time prolonged, neutrophil count decreased, platelet count decreased 
Podaljšan čas krvavitve, zmanjšano število nevtrofilcev, zmanjšano število trombocitov * Informacije, v literaturi navedene za ASA s pogostnostjo “ni znana”.
If you are breast-feeding or planning to breast-feed, talk to your doctor before taking this medicine. 
Če jemljete to zdravilo se o dojenju posvetujte s svojim zdravnikom.
Clopidogrel is extensively metabolised by the liver. 
Salicilna kislina se v jetrih predvsem konjugira.